革命药品公司的达拉克森在胰腺癌试验中显示出有前途的结果. Revolution Medicines' daraxonrasib shows promising results in pancreatic cancer trial.

革命药物公司宣布了达拉克松的第三期试验结果, 这是一种用于胰腺癌的研究性药丸. Revolution Medicines announced positive results from a Phase 3 trial for daraxonrasib, an investigational pill for pancreatic cancer. 这项研究显示,服用该药物的患者中位数无进展生存期为13. 2个月,是标准化疗患者的两倍多. The study showed patients taking the drug had a median progression-free survival of 13.2 months, more than double that of those on standard chemotherapy. 药物也获得了FDA的认可,并导致公司股价升34%. The drug also received FDA designations and caused the company's stock to surge over 34%.